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Abstract. There is strong evidence that the angiopoietin
family is involved in the regulation of tumour progression,
cellular growth and differentiation. Recently, it has been
reported that angiopoietin-like 4 (ANGPTL4) in cancer cell
promotes the metastatic process by increasing vascular perme-
ability. To elucidate ANGPTL4 expression and its association
with clinicopathological factors and prognosis in human gastric
adenocarcinomas, we examined 103 cases of surgically-
resected human gastric adenocarcinoma by immunohisto-
chemistry. Among 103 cases of adenocarcinoma, 38 cases
(36.9%) showed positive staining in the cytoplasm of the
carcinoma cells for ANGPTL4. Histologically, papillary and
mucinous adenocarcinomas showed relatively high expression
of ANGPTL4 (60 and 60%, respectively). The expression of
ANGPTL4 was correlated with the depth of tumour invasion
(p<0.005), lymph node metastasis (p<0.001), venous invasion
(p<0.00005) and TNM stage (p<0.001) in the total carcinoma.
In univariate survival analysis, ANGPTL4 expression was
not associated with the overall survival. RT-PCR or Western
blot analysis showed the expression of mRNA or protein of
ANGPTL4 in all four surgically-resected samples and all
four cell lines of human gastric adenocarcinoma. ANGPTL4
expression was correlated with several clinicopathological
factors, especially venous invasion. These findings suggest
that the ANGPTL4 is one of the factors involved in the
progression of human gastric cancer.
Introduction
Gastric cancer is one of the most common cancer types in the
world today, in spite of the fact that its incidence has shown a
gradual decline in many countries (1). The occurrence and
progression of cancer are considered to be a series of genetic
events affecting the structure and/or expression of a number
of oncogenes, tumour suppressors and growth factors (2,3).
The deep invasive carcinomas, such as gastric cancer, have
higher rates of lymph duct and venous invasions and lymph
node metastasis (4). However, the mechanisms of invasion
and metastasis of gastric carcinoma are not fully understood.
The molecular mechanisms in tumour progression, local
invasion and the formation of tumour metastases represent a
major challenge in cancer research. Metastasis of tumour
cells is the primary cause of death in patients with cancer (5).
To metastasize, tumour cells undergo a multistep progression
through a series of sequential and selective events (6). The
metastatic process consists of tumour cell detachment, local
invasion, motility, angiogenesis, vessel invasion, survival in
the circulation, adhesion to endothelial cells, extravasation and
regrowth in different organs (7). In each step, causative mole-
cules have been identified; these include cell-adhesion mole-
cules, various growth factors, matrix degradation enzymes
and motility factors, of which most of these can be regarded
as prognostic factors (7).
There is strong evidence that the angiopoietin family is
involved in the regulation of tumour progression, cellular
growth and differentiation (8-10). Angiopoietin-like 4
(ANGPTL4) is a member of the family of angiopoietins and
is known as hepatic fibrinogen/angiopoietin-related protein
(HEARP) (11), peroxisome proliferator-activated receptor-Á
(PPARÁ) angiopoietin-related gene (PGAR) (12) or fasting-
induced adipose factor (FIAF) (13). Similar to angiopoietins
and other angiopoietin-like proteins, ANGPTL4 contains an
amino-terminal coiled-coil domain and a carboxyl-terminal
fibrinogen-like domain (14). Oligomerized ANGPTL4
undergoes proteolytic processing to release its carboxyl
fibrinogen-like domain, which circulates as a monomer (14).
ANGPTL4 is a circulating plasma protein, expressed in
the liver, adipose tissue and placenta, as well as in ischemic
tissue (12,13), and induces a strong proangiogenic response,
independently of vascular endothelial growth factor (15).
ANGPTL4 is known as a gene with hypoxia-induced expres-
sion in endothelial cells. This protein is up-regulated by
fasting and peroxisome proliferator-activated receptor agonists,
associates with lipoproteins (12), and is involved in regulating
glucose homeostasis, insulin sensitivity and lipid metabolism
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through its capacity to inhibit lipoprotein lipase (12,16-18).
However, the role of ANGPTL4 is not clarified in cancer
biology, although the role of ANGPTL4 has been well charac-
terized in ischemic conditions and lipid metabolism.
Recently, it has been reported that the induction of
ANGPTL4 by TGF-ß primes breast cancer for lung metas-
tasis (19). Tumour cell-derived ANGPTL4 disrupts vascular
endothelial cell-cell junctions, increases the permeability of
lung capillaries, and facilitates the trans-endothelial passage
of cancer cells. Secretion of ANGPTL4 enables tumour cells
to extravasate into other tissue and to seed micrometastases.
However, it has been also reported that ANGPTL4 prevents
the metastatic process by inhibiting vascular activity as well
as tumour cell motility and invasiveness (20,21). The effects
of ANGPTL4 in experimental systems are still unclear in
tumour biology.
The objective of the present study is to evaluate the role
of ANGPTL4 in the progression and differentiation of human
gastric carcinoma, especially with regard to migration to vascu-
lature and distant metastasis to other organs.
Materials and methods
Patients. We studied 103 primary human gastric adeno-
carcinomas: 22 mucosal carcinomas (pTis), 33 submucosal
infiltrative carcinomas (pT1), 11 carcinomas invading proprial
muscle layers (pT2), 15 carcinomas penetrating serosa (pT3)
and 22 carcinomas invading adjacent structures (pT4). All
tumour specimens were obtained from patients operated at
Nagasaki University Hospital between 1998 and 2007. Each
tumour was assigned a histological type according to the
Japanese Classification of Gastric Carcinoma by the Japanese
Research Society for Gastric Cancer (22), based on World
Health Organization classification (23) and a depth grading
of infiltration according to the International Union Against
Cancer (UICC), TNM Classification of Malignant Tumors
(24). The study had ethical approval from the Local Research
Ethics Committee. The study was conducted in accordance
with the Helsinki Declaration. Histologically, of the 103
primary human gastric adenocarcinomas, 5 were papillary
adenocarcinomas (pap), 20 were tubular adenocarcinomas of
the well-differentiated type (tub/wel), 33 were tubular adeno-
carcinomas of the moderately differentiated type (tub/mod),
13 were poorly differentiated adenocarcinomas of the solid
type (por/solid), 11 were poorly differentiated adenocarci-
nomas of the non-solid type (por/non-solid), 16 were signet-
ring cell carcinomas (sig) and 5 were mucinous adenocarci-
nomas (muc).
We used 10 adenomas as benign lesions with moderate
dysplasia resected by endoscopic mucosal resection (EMR).
Fifteen specimens of normal gastric mucosal tissue were
evaluated as normal controls. The desmoplastic stromal
reaction was graded according to the extent of the stromal
area involved. It was defined as ‘slight’ (when the fibrous
stromal area was <25% of the whole tumour), ‘moderate’
(between 25 and 75%) and ‘extensive’ (when it exceeded
75% of the whole tumour) based on the overall pattern (25).
The examination was performed on routine slides to identify
lymphatic and venous invasion. In addition to hematoxylin
and eosin staining, we also used elastic Van Gieson staining
and immunohistochemical staining for CD34 and D2-40 in
all cases. Each parameter was defined as ‘present’ when
invasion was identified with certainty, but defined as ‘absent’
when it was either not observed at all or not observed with
certainty (26,27). Lymph node metastasis was defined as
‘present’ only when histologically proven. Diagnosis was
established by two independent pathologists (T. Nakayama
and T. Taguchi), and cases of questionable diagnosis were
omitted from the study.
Among the 103 patients, 57 were used for the follow-up
study. In 103 cases, 46 cases were deleted for survival
analysis (22 cases of pTis that did not show any invasion to
stroma. Three cases died within 7 days after surgery.
Twenty-one cases had no data on follow-up). Forty-four
patients remained disease-free for a median follow-up period
of 1301 days, ranging from 150 to 3318 days. In total, 13
patients suffered from local recurrence (7 patients) or distant
metastasis (6 patients) after the operation.
Immunohistochemistry. Formalin-fixed and paraffin-embedded
tissues were cut into 4 μm sections, deparaffinized in xylene,
and rehydrated in phosphate-buffered saline. Deparaffinized
sections were preincubated with normal rabbit serum to prevent
non-specific binding, and then incubated overnight at 4˚C
with an optimal dilution (0.1 μg/ml) of a primary polyclonal
goat antibody against human ANGPTL4 (R&D Systems, Inc.,
Minneapolis, MA). The slides were sequentially incubated
with a biotinylated rabbit anti-goat immunoglobulin antibody
and the reaction products were viewed using diaminoben-
zidine (DAB; Dako Ltd., Glostrup, Denmark) and hematoxylin
staining as counter staining. Primary antibody preabsorbed
with excess recombinant ANGPTL4 peptides (R&D Systems,
Inc.) was used as negative controls. Human liver tissue served
as the internal positive control for ANGPTL4 immunostaining
(12). Analysis of the immunohistochemical staining was
performed independently by two investigators (T. Nakayama
and T. Taguchi). ANGPTL4 expression was classified into two
categories depending on the percentage of cells stained: -, 0-
10% positive cells; +, >10% positive tumour cells.
Cell culture. MKN-1, MKN-28, NUGC-3 and SCH cell lines
derived from human gastric cancer, were obtained from the
Human Health Resources Bank (Osaka, Japan) (28). All cell
lines were maintained in RPMI-1640 (Invitrogen Corp.,
Carlsbad, CA) supplemented with heat-inactivated 10% fetal
calf serum (Invitrogen Corp.) and 2 mM glutamine (Invitrogen
Corp.), and incubated at 37˚C in a humidified atmosphere
containing 5% CO2.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total RNA was prepared from four human gastric cancer
tissues and the human gastric carcinoma cell lines MKN-1,
MKN-28, NUGC-3 and SCH (28) using the acid guanidine
phenol method (29). Cellular RNA (1 μg) was incubated at
37˚C for 1 h in 50 μl of reverse transcriptase buffer containing
20 units of RNAsin (Promega Corp., Madison, WI), 100 pmol
of random hexamer primers (Boehringer Mannheim,
Mannheim, Germany) and 400 units of Moloney murine
leukemic virus reverse transcriptase (Invitrogen Corp.). Reverse
transcription was terminated by heating at 95˚C for 10 min
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and 20% of the resultant cDNA was removed for PCR. PCR
samples were incubated with 50 pmol of each primer and
2.5 units of TaqDNA polymerase. The human ANGPTL4
PCR primers were 5'-GGCGAGTTCTGGCTGGGTCT-3'
(sense) and 5'-TGGCCGTTGAGGTTGGAATG-3' (anti-
sense). The human ß-actin PCR primers were 5'-TCCTCC
CTGGAGAAGACTA-3' (sense) and 5'-AGTACTTGCGC
TCAGGAGGA-3' (antisense). The ANGPTL4 and ß-actin
primers were predicted to amplify 329 and 313 bp DNA
fragments, respectively. Both primer pairs were chosen to
span introns of their respective human genes. Samples were
subjected to 30 cycles of PCR amplification using a thermo-
cycler. Each cycle included denaturation at 94˚C for 1 min,
annealing at 60˚C for 1 min and primer extension at 72˚C for
1.5 min. An aliquot of each amplification mixture was sub-
jected to electrophoresis on a 1.5% agarose gel and DNA was
visualized by ethidium bromide staining.
Western blot analysis. Western blot analysis was performed
on human gastric cancer tissues and cell lines. The tissues
obtained at surgery were frozen immediately after tissue
sampling. The tissues and the cells were then suspended in
RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate and 0.05% SDS, pH 7.4), broken into
pieces on ice, and subjected to three freeze-thaw cycles. The
insoluble tissue debris was removed by centrifugation at
14000 x g at 0˚C for 10 min. The cell pellets were lysed in
lysis RIPA buffer containing 50 mM Tris, 150 mM NaCl, 1%
NP-40 and 0.25% sodium deoxycholate. The cells were then
cleared by centrifugation at 14000 x g at 0˚C for 10 min and
sample buffer was added. The supernatant was collected and
the protein concentration was quantified using a protein assay
reagent (Bio-Rad Laboratory, Hercules, CA). After boiling,
the proteins (20 μg) were separated by polyacrylamide gel
electrophoresis (PAGE) under denaturing and reducing
conditions, and transferred to a Hybond ECL Nitrocellulose
Membrane (Amersham Pharmacia Biotech, Arlington Height,
IL). The membranes were rinsed in TBS, blocked with 5%
low-fat dried milk in TBS containing 0.1% Tween-20 (TBS-T),
and then incubated for 6 h at room temperature with a 1:500
dilution of the anti-human ANGPTL4 antibody (R&D Systems,
Inc.). The anti-human ß-actin antibody (Santa Cruz Biotechno-
logy, Inc., Santa Cruz, CA) was used as an indicator for the
amount of loading proteins. After extensive washing with
TBS-T, the membranes were incubated for 1 h with a 1:1000
dilution of the horseradish-peroxidase-conjugated donkey
anti-rabbit immunoglobulin G (Santa Cruz Biotechnology,
Inc.) in TBS-T containing 3% low-fat dried milk. The mem-
branes were washed and developed with a horseradish
peroxidase chemiluminescence detection reagent (ECL Plus
System, Amersham Pharmacia Biotech) and then exposed to
Hyperfilm ECL (Amersham Pharmacia Biotech).
Statistical analysis. The Stat View II Program (Abacus
Concepts, Inc., Berkeley, CA) was used for statistical
analyses. Analyses comparing the expression of ANGPTL4
were performed by the ¯2 test for independence or Fisher's
exact probability test, the Mann-Whitney's U test. Survival
durations were calculated using the Kaplan-Meier method. A
log-rank test was used to calculate the significance of dif-
ferences in the survival analysis. A probability level of <0.05
was considered to indicate a significant difference.
Results
The expression of ANGPTL4 in normal gastric tissue detected
by immunohistochemical staining. In normal gastric tissue,
ANGPTL4 was expressed in the chief cells of fundic gland
and was not expressed in the cells of pyloric gland, the surface
lining cells with mucin production, nor the mucosa with
intestinal metaplasia (Fig. 1A). Further, ANGPTL4 was also
expressed faintly in neural cells in submucosal and myenteric
plexus (Fig. 1B). Human liver tissue served as the internal
positive control for ANGPTL4 immunostaining (Fig. 1C).
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Figure 1. Immunohistochemical staining for ANGPTL4 in human gastric
tissue. ANGPTL4 is expressed in cytoplasm of the chief cells of fundic
gland (A) and neural cell of myenteric plexus (B). Human liver tissue is
shown as positive control for immunostaining (C). [Magnification: x20 (A),
x100 (B), x100 (C)].
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Immunohistochemical analyses of clinicopathological factors.
We have summarized the immunohistochemical results in
Tables I and II. Only one of ten adenomas cases with mode-
rate dysplasia resected by endoscopic mucosal resection
(EMR) had positive staining for ANGPTL4 (Table I). Among
103 cases of adenocarcinoma, 38 cases (36.9%) showed
positive staining for ANGPTL4 in the cytoplasm of carcinoma
cells (Fig. 2). Also, the invasive component of the primary
tumour was more intensely stained than the superficial part
of the tumour in almost all cases of invasive carcinoma.
Histologically, papillary adenocarcinoma showed relatively
high expression of ANGPTL4 (60%) (Table I). However,
only two cases (12.5%) of 16 signet-ring cell carcinomas
showed positive staining for ANGPTL4. The expression of
ANGPTL4 was not correlated with the degree of histological
differentiation.
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Tubular adenoma 10 1 (10.0) 9 (90.0)
Total carcinoma 103 38 (36.9) 65 (63.1)
Histological differentiation
i) Papillary 5 3 (60.0) 2 (40.0) n.s.
Tubular/well 20 8 (40.0) 12 (60.0)
Tubular/mod 33 12 (36.4) 21 (63.6)
Poor/solid 13 6 (46.2) 7 (53.8)
Poor/non-solid 11 4 (36.4) 7 (63.8)
Signet-ring cell 16 2 (12.5) 14 (87.5)
Mucinous 5 3 (60.0) 2 (40.0)
ii)Intestinal type 58 23 (39.7) 35 (60.3) n.s.
Diffuse type 45 15 (33.3) 30 (66.7)
Depth of tumour invasion
pTis 22 4 (18.2) 18 (81.8) p<0.005a
pT1 33 9 (27.3) 24 (72.7)
pT2 26 13 (50.0) 13 (50.0)
pT3 21 12 (57.1) 9 (42.9)
pT4 1 0 (0.0) 1 (100)
Lymph node metastasis
Present 29 18 (62.1) 11 (37.9) p<0.001b
Absent 74 20 (27.0) 54 (73.0)
Lymph duct invasion
Present 64 30 (46.9) 34 (53.1) p<0.01b
Absent 39 8 (20.5) 31 (79.5)
Venous invasion
Present 47 28 (59.6) 19 (40.4) p<0.00005b
Absent 56 10 (17.9) 46 (82.1)
TNM-stage
0 22 4 (18.2) 18 (81.8) p<0.001a
1a 32 9 (28.1) 23 (71.9)
1b 17 6 (35.3) 11 (64.7)
2 8 3 (37.5) 5 (62.5)
3a 13 9 (69.2) 4 (30.8)
3b 6 5 (83.3) 1 (16.7)
4 5 2 (40.0) 3 (60.0)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
n.s., not significant. aMann-Whitney's U test; b¯2 for independence test.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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The degree of immunoreactivity appears to be correlated
with the degree of tumour invasion (Table I). Statistical
analysis showed significant correlation with the TNM staging
(p<0.001). Further, ANGPTL4 expression was correlated
with the presence of lymph node metastasis (p<0.001) and
lymph duct invasion (p<0.01) in the total carcinoma. In parti-
cular, the expression of ANGPTL4 was significantly correlated
with venous invasion (p<0.00005). In 86 cases of invasive
carcinoma, ANGPTL4 expression was correlated with the
desmoplastic stromal reaction (p<0.05), and with the tumour
growth pattern (p<0.05) (Table II).
Overall survival analysis and prognosis after surgery. We
analyzed overall survival in 57 patients with invasive carci-
noma based on their expression of ANGPTL4 in human
gastric cancer. However, ANGPTL4 expression was not
associated with the overall survival by Kaplan-Meier method
(p=0.086 in log-rank test) (Fig. 3).
ANGPTL4 immunoreactivity was compared with the
prognosis after surgery in 57 patients that were also analyzed
for overall survival (Table III). ANGPTL4 expression was
found in 43.2% (19/44) of disease-free and in 46.2% (6/13)
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Table II. Tumour invasive pattern and ANGPTL4 expression in invasive cancer (86 cases).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
n + - P-value
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Invasive cancer 86 36 (41.9) 50 (58.1)
Desmoplastic stromal reaction
Slight 15 10 (66.7) 5 (33.3) <0.05a
Moderate 44 19 (43.2) 25 (56.8)
Extensive 27 7 (25.9) 20 (74.1)
Tumour growth pattern
Solid 17 11 (64.7) 6 (35.3) <0.05a
Intermediate 35 14 (40.0) 21 (60.0)




Figure 2. Immunohistochemical staining for ANGPTL4 in human gastric
cancer. Positive staining for ANGPTL4 in cytoplasm of human gastric
cancer. (A) Well-differentiated adenocarcinoma, (B) moderately-differentiated
adenocarcinoma and (C) poorly-differentiated adenocarcinoma (non-solid
type) of human gastric cancer. [Magnification: x100 (A), x100 (B) and x100
(C)].
Figure 3. Overall survival based on the expression of ANGPTL4 in human
gastric cancer (57 cases). ANGPTL4 expression was not associated with the
overall survival in univariate survival analysis (p=0.086 in log-rank test).
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of recurrence or metastasis cases and the expression of
ANGPTL4 was not significantly different between disease-
free and the sum of local recurrence and distant metastasis
cases. Moreover, among 13 patients with local recurrence or
distant metastasis, 7 patients (53.8%) were locally recurred
(Table III). Noteworthily, all these cases with local recurrence
were negative for ANGPTL4, while the remaining 6 patients
(46.2%, 6/13) suffered distant metastasis to other organs: 2 of
lung, 2 of liver, 1 of brain and 1 of spinal cord. These cases
all showed positive staining for ANGPTL4. The expression
of ANGPTL4 was statistically correlated with the presence
of distant metastasis to other organs (p<0.001).
RT-PCR and Western blotting for ANGPTL4 in human gastric
tissues and cultured cell lines. RT-PCR showed mRNA
expression of ANGPTL4 and Western blot analysis showed
intense expression of ANGPTL4 protein in all 8 surgically-
resected samples, 4 normal mucosas, 4 invasive carcinomas
and all four cultured cell lines of human gastric adenocarci-
noma (Fig. 4A and B, respectively). Expression of ANGPTL4
protein in invasive carcinoma was more intense than in normal
mucosa in every case (Fig. 4B).
Discussion
The tumour microenvironment plays an important role in
molecular mechanism of metastasis (30). Primary carcinomas,
as well as metastases, are comprised of both tumour cells and
cells of the stroma including fibroblasts, endothelial cells,
and inflammatory cells. The cytokine TGF-ß is produced by
stromal cells of the tumour microenvironment in response to
hypoxia or inflammation or by carcinoma-associated fibro-
blasts (31). Recently, Padua et al showed that TGF-ß stimu-
lates expression of the adipokine ANGPTL4 by activating
SMAD transcription factors (19). Tumour cell-derived
ANGPTL4 disrupts vascular endothelial cell-cell junctions,
increases the permeability of capillaries, and facilitates the
trans-endothelial passage of tumour cells. Secretion of
ANGPTL4 enables tumour cells to extravasate into other
tissue and to seed micrometastases. ANGPTL4 contains an
amino-terminal coiled-coil domain and a carboxyl-terminal
fibrinogen-like domain. Oligomerized ANGPTL4 undergoes
proteolytic processing to release its carboxyl fibrinogen-like
domain, which circulates in serum (14). In this study, the
expression of ANGPTL4 protein in tissues from all 4 cases
of invasive carcinomas was more intense than normal tissue
(Fig. 4B). ANGPTL4 may promote the vascular invasion and
the distant metastasis in human gastric cancer through the
activation of fibrinogen-like domein of ANGPTL4.
The angiopoietin family of growth factors has recently
been identified as ligands for Tie-2. Angiopoietin (Ang)-1
activates Tie-2 leading to receptor autophosphorylation upon
binding and also stimulates endothelial cell migration in vitro
(32,33). Ang-2 appears to be a natural inhibitor of Tie-2
function, binding to Tie-2 with an affinity similar to that of
Ang-1 and blocks Ang-1-stimulated receptor phosphorylation
in endothelial cells (33,34). Deletion of the Ang-1 gene or
overexpression of Ang-2 in transgenic mice results in death
in utero due to a widespread failure of microvascular morpho-
genesis similar to that observed in Tie-2 knock-out mice
(34-36). Ang-3 and Ang-4 are more recently described
members of this family that seem to represent the mouse and
human counterparts of the same genetic locus (37). Ang-4
seems to act as an agonist for the Tie-2 receptor and is
expressed at high levels in lung (37). However, in contrast to
other proteins of the angiopoietin family, ANGPTL4 does
not bind the Tie-2 receptor and the receptor for ANGPTL4 is
still unknown. The role of the ANGPTL4 has not been fully
clarified in cancer biology, particularly the relationship
between the expression of ANGPTL4 and the clinicopatho-
logical features of human cancer.
There are few reports on ANGPTL4 protein or gene
expression profile in cell lines of breast cancer (19,38), lung
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Figure 4. RT-PCR for ANGPTL4 in human gastric cancer: tissues and cell
lines (A). M, 100 bp ladder marker (Invitrogen, Inc.). The expression of
ANGPTL4 in human gastric cancer tissues and cultured cell lines by
Western blotting (B). Human gastric cancer tissues (1-8) and human gastric
cancer cell lines (9-12). (1, normal gastric tissue, Case-1; 2, cancer tissue,
Case-1; 3, normal gastric tissue, Case-2; 4, cancer tissue, Case-2; 5, normal
gastric tissue, Case-3; 6, cancer tissue, Case-3; 7, normal gastric tissue,
Case-4; 8, cancer tissue, Case-4; 9, MKN-1; 10, MKN-28; 11, NUGC-3; 12,
SCH).




Total cases 57 25 (43.9) 32 (56.1)
Disease-free 44 19 (43.2) 25 (56.8) n.s.
Recurrence or distant metastasis 13 6 (46.2) 7 (53.8)
Local recurrence 7 0 (0.0) 7 (100) p<0.001a
Distant metastasis 6 6 (100) 0 (0.0)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
n.s., not significant. aFisher's exact probability test.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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cancer (20), hepatocellular carcinoma (39), prostate cancer
(40) and melanoma (21). Angiopoietin family members
usually regulate the differentiation or invasion of cancer cells
through the activation of its receptor Tie-2 and downstream
tyrosine kinase pathway (8,9,41). However, ANGPTL4 does
not bind to Tie-2 but contains motifs structurally conserved
in angiopoietins. In this study, we investigated the expression
of ANGPTL4 in human gastric cancer using immunohisto-
chemical and molecular biological techniques. This is the
first investigation of the role of ANGPTL4 in human gastric
cancer.
In cancer research, tumour progression, local invasion
and tumour metastases determine the prognosis of cancer
patients. Although the cellular mechanisms of metastasis
affect the different tumour cell properties (42,43), the important
initial step of cancer metastasis is the invasion into the
capillary and/or lymph duct through the tight endothelial
junctions. Some factors, such as growth factors and cytokines
derived from cancer cell, change the vascular permeability
(44,45). Statistical analyses of our data showed a correlation
between ANGPTL4 expression and venous invasion, lymph
duct invasion, and metastasis to lymph nodes (Table I). The
cancer cells with venous invasion showed strong immuno-
positivity for ANGPTL4 proteins in the cytoplasm of carci-
noma cells. One report have described that ANGPTL4 up-
regulates the infiltration into the capillary adjacent to the
tumour due to acute disruptions of the endothelial cell-cell
junctions caused by ANGPTL4 (19). Further, the strong
interaction of ANGPTL4 with the subendothelial extracellular
matrix (ECM) is heparin/heparan sulfate proteoglycan-
dependent (46). The balance between matrix-associated and
soluble forms of ANGPTL4 points to the role of the ECM in
the regulation of its bioavailability (46). Our study strongly
supports the previous report that ANGPTL4 promotes the
capillary and/or lymph duct invasion as the first step of cancer
metastasis.
Tumour desmoplasia is a common feature in several
malignant human tumours and it has been reported that a
poorly defined tumour border at the invasive tumour edge is
associated with a poorer prognosis in colorectal cancer (47).
Carcinoma cell/stromal cell interaction is important for the
processes of carcinoma invasion and metastasis (48). However,
there was no report of the relationship between the stromal
reaction and the expression of ANGPTL4 in cancer. In this
study, although many cases of gastric carcinoma expressed
ANGPTL4 in the cytoplasm of malignant cells, fibrous stromal
cells did not show any expression of ANGPTL4 (data not
shown). Moreover, the expression of ANGPTL4 in carcinoma
cells was significantly inversely correlated with the extent of
fibrous stromal tissue. Our results suggest that the expression
of ANGPTL4 protein has potential as one of many prognostic
factors in gastric cancer.
ANGPTL4 expression was not associated with the overall
survival by log-rank test (Fig. 3). However, survival rate was
relatively better in the patients without expression of
ANGPTL4. In this study, only 57 cases were investigated
and included many cases with short-term follow-up. Further
investigation for the detailed prognostic evaluation using
substantially more cases is warranted. The expression of
ANGPTL4 correlates with venous invasion, which may lead
to distant metastasis to other organs through blood flow (19).
In this study, the cause of death in 6 of the follow-up cases
was distant metastasis to other organs, such as liver, lung, or
brain (Table III). Further, all 6 cases with distant metastases
were positive for ANGPTL4. We hypothesized worse
survival outcome of the patients with ANGPTL4 due to the
high incidence of distant metastasis. However, there was no
statistical difference in overall survival of patients with or
without ANGPTL4. Prognostic investigation showed
specifically that 7 cases without ANGPTL4 in 13 patients of
cancer related-death showed local recurrence (Table III).
Some reports indicated that ANGPTL4 regulates the cell
motility and invasiveness (20,21). These findings suggest
that the carcinoma with ANGPTL4 is more susceptible to
distant metastasis and the carcinoma without ANGPTL4
shows a tendency for stromal invasion. The examination of
ANGPTL4 in carcinoma tissue may predict the incidence
of distant metastasis in human gastric cancer. However, only
57 cases were investigated for follow-up in this study.
Further investigation for the detailed prognostic evaluation
is needed.
ANGPTL4 was expressed in human gastric adenocarci-
noma and was correlated with several clinicopathological
factors, especially venous invasion and distant metastasis.
These findings suggest that ANGPTL4 is one of the factors
involved in the progression of human gastric cancer. However,
the detailed mechanisms of ANGPTL4 protein in human
gastric cancer requires further investigation.
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